Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10881236 | 0.83 | PSMB8 (0.70) | PSMB8MAPTNPC1RAB9ATP53 | |
| SCHEMBL5968335 | 0.83 | PSMB8 (0.70) | PSMB8MAPTNPC1RAB9ATP53 | |
| SCHEMBL3083786 | 0.81 | PSMB8 (0.68) | PSMB8MAPTNPC1RAB9ATP53 | |
| SCHEMBL717589 | 0.79 | PSMB8 (0.66) | PSMB8MAPTNPC1RAB9ATP53 | |
| SCHEMBL6960612 | 0.79 | PSMB8 (0.66) | PSMB8MAPTNPC1RAB9ATP53 | |
| SCHEMBL548913 | 0.79 | PSMB8 (1.00) | PSMB8MAPTNPC1RAB9ATP53 | |
| SCHEMBL105029 | 0.76 | NPC1 (0.54) | PSMB8MAPTNPC1RAB9ATP53 | |
| SCHEMBL12469476 | 0.75 | PSMB8 (0.59) | PSMB8MAPTNPC1RAB9ATP53 | |
| SCHEMBL11221096 | 0.74 | NPC1 (0.52) | PSMB8MAPTNPC1RAB9ATP53 | |
| SCHEMBL10670777 | 0.74 | NPC1 (0.52) | PSMB8MAPTNPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | claimed |
| CN-115433203-A | Amine fluorinated curcumenol derivative compound and application and preparation method thereof | 华东理工大学 | 2022-12-06 | — | — | CN | claimed |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | MONASH UNIVERSITY (AU) | 2022-01-18 | — | — | US | claimed |
| US-20180334440-A1 | INHIBITORS OF ARGININE GINGIPAIN | Cortexyme, Inc. (US) | 2018-11-22 | — | — | US | claimed |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | MONASH UNIVERSITY (AU) | 2018-10-04 | — | — | US | claimed |
| EP-3374352-A1 | INHIBITORS OF ARGININE GINGIPAIN | Cortexyme, Inc. (US) | 2018-09-19 | — | — | EP | claimed |
| EP-3356387-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | Monash University (AU) | 2018-08-08 | — | — | EP | claimed |
| US-9896452-B2 | Substituted prolines/piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | claimed |
| WO-2017201322-A1 | TREATMENT OF OSTEOARTHRITIS WITH GINGIPAIN BLOCKING AGENTS | Cortexyme, Inc. (US) | 2017-11-23 | — | — | WO | claimed |
| EP-3204352-A2 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2017-08-16 | — | — | EP | claimed |
| EP-2811997-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | Eolas Therapeutics Inc. (US) | 2014-12-17 | — | — | EP | claimed |
| WO-2013119639-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | EOLAS THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | claimed |
| WO-2008129129-A1 | HETEROCYCLIC PHENYL CARBAMATES AS NOVEL FAAH-INHIBITORS | KUOPION YLIOPISTO (FI) | 2008-10-30 | — | — | WO | claimed |
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | claimed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | claimed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | claimed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | claimed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | claimed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | claimed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | VIP, PNKP, PEPD | PSMB8 246/4885MAPT 4514/4885NPC1 2542/4885 |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | PSMB8 3381/4885MAPT 4059/4885NPC1 3036/4885 |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | VIP, PNKP, PEPD | PSMB8 246/4885MAPT 4514/4885NPC1 2542/4885 |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | PSMB8 571/4885MAPT 2065/4885NPC1 37/4885 |
| US-20180334440-A1 | INHIBITORS OF ARGININE GINGIPAIN | ARGLU1, ENPEP, PRAP1 | PSMB8 4385/4885MAPT 969/4885NPC1 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.